Notes
see Reactions 1488 p2; 803098972
Reference
EMA. Refusal of the marketing authorisation for Nerventra (laquinimod). Internet Document : [2 pages], 23 May 2014. Available from: URL: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002546/WC500160120.pdf
Rights and permissions
About this article
Cite this article
CHMP reaffirms licensing refusal for laquinimod in RRMS. Reactions Weekly 1504, 2 (2014). https://doi.org/10.1007/s40278-014-1195-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-014-1195-9